https://mindmedicinelaw.com/briefing/mechanistic-insights-on-psychedelic-effects-in-mental-health-20260624-16409The Psychedelic Journalen2026-06-25T15:05:38.891334+00:00Mechanistic Insights on Psychedelic Effects in Mental Healthpsychedelic research, therapeutic effects, mental health, psychoactive side effects, neuroscience, clinical trials, drug development, regulatory frameworks, neural pathways, public healthhttps://mindmedicinelaw.com/briefing/ketamine-routes-for-trd-efficacy-safety-and-dosing-insights-20260624-16343The Psychedelic Journalen2026-06-25T15:05:10.690977+00:00Ketamine Routes for TRD: Efficacy, Safety, and Dosing Insightstreatment-resistant depression, ketamine administration, intravenous ketamine, intranasal esketamine, clinical trials, safety monitoring, depression treatmenthttps://mindmedicinelaw.com/briefing/oral-ketamine-trial-for-depression-mixed-results-in-eu-20260624-16342The Psychedelic Journalen2026-06-25T15:04:57.875131+00:00Oral Ketamine Trial for Depression: Mixed Results in EUoral ketamine, treatment-resistant depression, KET01 trial, rapid antidepressant effects, ketamine safety, depression treatment, clinical trials, neuroscience, mental health, pharmaceutical researchhttps://mindmedicinelaw.com/briefing/psilocybin-vs-ssris-depression-treatment-insights-20260624-16258The Psychedelic Journalen2026-06-24T22:05:01.111091+00:00Psilocybin vs SSRIs: Depression Treatment Insightspsilocybin, SSRIs, depression treatment, psychedelic research, clinical trials, mental health, serotonin pathways, Controlled Substances Act, psychedelic therapy, treatment protocolshttps://mindmedicinelaw.com/briefing/ketamine-s-abuse-potential-in-mood-disorder-treatment-20260624-16241The Psychedelic Journalen2026-06-24T22:04:29.208415+00:00Ketamine's Abuse Potential in Mood Disorder Treatmentketamine, mood disorders, abuse potential, clinical guidelines, regulatory policies, NMDA receptor, antidepressant, public health, substance misuse, treatment protocolshttps://mindmedicinelaw.com/briefing/dea-corrects-bromazolam-schedule-i-placement-for-clarity-20260624-15971The Psychedelic Journalen2026-06-24T15:06:01.021127+00:00DEA Corrects Bromazolam Schedule I Placement for ClarityDEA, bromazolam, Schedule I, Controlled Substances Act, chemical nomenclature, regulatory clarity, drug policy, legal enforcement, substance classification, psychedelic researchhttps://mindmedicinelaw.com/briefing/dea-schedules-o-desmethyltramadol-as-schedule-i-substance-20260624-15970The Psychedelic Journalen2026-06-24T15:04:41.267993+00:00DEA Schedules O-Desmethyltramadol as Schedule I SubstanceDEA scheduling, O-Desmethyltramadol, Schedule I substances, drug regulation, pharmaceutical industry, psychedelic research, compliance, controlled substances, temporary scheduling, market implicationshttps://mindmedicinelaw.com/briefing/real-world-data-on-esketamine-for-depression-insights-and-implications-20260623-16347The Psychedelic Journalen2026-06-25T15:06:05.256831+00:00Real-World Data on Esketamine for Depression: Insights and Implicationsintranasal esketamine, treatment-resistant depression, real-world data, clinical effectiveness, safety profile, psychedelic research, depression treatment, glutamate pathways, mental health policy, patient demographicshttps://mindmedicinelaw.com/briefing/cyp2d6-polymorphisms-influence-dmt-and-harmine-metabolism-20260623-16362The Psychedelic Journalen2026-06-25T15:05:52.514343+00:00CYP2D6 Polymorphisms Influence DMT and Harmine MetabolismCYP2D6 polymorphisms, DMT metabolism, harmine pharmacokinetics, ayahuasca therapy, personalized psychedelic therapy, clinical trial design, genetic variations, PBPK modeling, psychedelic research, drug metabolismhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-postoperative-sleep-for-thoracic-surgery-20260623-16176The Psychedelic Journalen2026-06-24T22:04:17.816866+00:00Esketamine's Role in Postoperative Sleep for Thoracic Surgeryesketamine, postoperative sleep, thoracic surgery, clinical trial, pain management, inflammatory markershttps://mindmedicinelaw.com/briefing/psychedelic-activists-challenge-restrictive-sharing-law-in-u-s-20260623-15946The Psychedelic Journalen2026-06-23T22:03:45.136817+00:00Psychedelic Activists Challenge Restrictive Sharing Law in U.S.psychedelic policy, referendum, drug regulation, community advocacy, psychedelic sharing, grassroots movements, public health, legal challenges, U.S. law, psychedelic researchhttps://mindmedicinelaw.com/briefing/serotonin-s-role-in-alcohol-use-disorder-implications-for-treatment-20260622-16136The Psychedelic Journalen2026-06-24T22:04:45.642860+00:00Serotonin's Role in Alcohol Use Disorder: Implications for Treatmentserotonin, alcohol use disorder, psychedelic-assisted therapy, 5-HT, biomarkers, personalized treatment, clinical trials, serotonergic dysregulation, AUD subtypes, neurosciencehttps://mindmedicinelaw.com/briefing/stroboscopic-light-stimulation-new-safety-data-in-depression-20260622-16135The Psychedelic Journalen2026-06-24T22:04:37.507632+00:00Stroboscopic Light Stimulation: New Safety Data in Depressionstroboscopic light stimulation, depression treatment, clinical trials, non-pharmacological intervention, mental health research, safety and tolerability, Phase 2a trial, SLS efficacy, trial design, psychedelic researchhttps://mindmedicinelaw.com/briefing/definium-s-lsd-therapy-advances-in-phase-3-depression-trial-20260622-16096The Psychedelic Journalen2026-06-24T15:04:29.960140+00:00Definium's LSD Therapy Advances in Phase 3 Depression TrialLSD therapy, Definium, Phase 3 trial, depression treatment, psychedelic research, regulatory approval, mental health, neuroplasticity, psychoactive effects, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-depression-treatment-current-insights-20260622-15879The Psychedelic Journalen2026-06-23T22:03:30.970419+00:00Ketamine's Role in Depression Treatment: Current Insightsketamine, depression treatment, treatment-resistant depression, suicidal ideation, NMDA receptor, antidepressant, clinical trials, long-term safety, synaptic plasticityhttps://mindmedicinelaw.com/briefing/opioid-receptor-activation-by-ketamine-and-pcp-implications-20260622-15878The Psychedelic Journalen2026-06-23T22:03:19.253949+00:00Opioid Receptor Activation by Ketamine and PCP: Implicationsketamine, PCP, opioid receptors, NMDAR, therapeutic potential, abuse potential, clinical guidelines, drug development, pharmacology, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/psychedelics-for-headache-treatment-systematic-review-insights-20260621-16197The Psychedelic Journalen2026-06-24T22:04:53.065135+00:00Psychedelics for Headache Treatment: Systematic Review Insightspsychedelics, systematic review, cluster headaches, migraines, serotonergic compounds, clinical trials, psilocybin, LSD, treatment efficacy, safety assessmenthttps://mindmedicinelaw.com/briefing/orexin-receptor-treatment-in-stress-models-new-insights-20260620-15867The Psychedelic Journalen2026-06-23T22:03:54.575245+00:00Orexin Receptor Treatment in Stress Models: New Insightsorexin receptor treatment, neuroplasticity, stress models, anxiety disorders, depression therapy, psychiatric disorders, basolateral amygdala, preclinical research, neurocircuitry, therapeutic approacheshttps://mindmedicinelaw.com/briefing/colorado-s-new-law-on-ibogaine-access-policy-implications-20260619-16095The Psychedelic Journalen2026-06-24T15:05:51.455687+00:00Colorado's New Law on Ibogaine Access: Policy ImplicationsColorado ibogaine law, psychedelic policy, ibogaine research, psychedelic therapy, legalization of psychedelics, psychedelic safety, 5-MeO-DMT history, psychedelic regulation, mental health treatment, addiction therapyhttps://mindmedicinelaw.com/briefing/adaptive-charge-modulation-in-spinal-cord-stimulation-20260618-15074The Psychedelic Journalen2026-06-23T22:04:14.249082+00:00Adaptive Charge Modulation in Spinal Cord Stimulationadaptive charge modulation, spinal cord stimulation, neuromodulation, deep tissue activation, clinical trials, neuroscience, neural interfaces, high-frequency stimulation, regulatory frameworks, chronic stabilityhttps://mindmedicinelaw.com/briefing/bayesian-optimization-enhances-lifu-neuromodulation-precision-20260618-15073The Psychedelic Journalen2026-06-23T22:04:03.826796+00:00Bayesian Optimization Enhances LIFU Neuromodulation PrecisionBayesian optimization, LIFU neuromodulation, BEACUN, functional ultrasound imaging, personalized medicine, clinical trialshttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-manual-dexterity-neuroscience-insights-20260617-16069The Psychedelic Journalen2026-06-24T15:06:21.385824+00:00Psilocybin's Impact on Manual Dexterity: Neuroscience Insightspsilocybin, manual dexterity, neuroscience, motor skills, clinical trials, therapeutic applications, psychedelic research, motor function, policy implications, safety considerationshttps://mindmedicinelaw.com/briefing/limits-of-pharmacotherapy-in-muscle-dysmorphic-disorder-20260617-15869The Psychedelic Journalen2026-06-24T15:06:11.174005+00:00Limits of Pharmacotherapy in Muscle Dysmorphic Disordermuscle dysmorphic disorder, pharmacotherapy, body dysmorphic disorder, selective serotonin reuptake inhibitors, emerging therapies, psychedelic-assisted therapy, clinical trials, neurobiological mechanisms, treatment efficacy, public health policyhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-traumatic-brain-injury-recovery-20260612-16386The Psychedelic Journalen2026-06-25T15:05:26.809144+00:00Psilocybin's Potential in Traumatic Brain Injury Recoverypsilocybin, traumatic brain injury, serotonin signaling, microglial density, psychedelic research, clinical trials, neuroscience, inflammation, TBI recovery, regulatory considerations